echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > JAMA Oncol: Comparison of the advantages and disadvantages of whole brain radiotherapy or stereotactic radiotherapy for brain metastases

    JAMA Oncol: Comparison of the advantages and disadvantages of whole brain radiotherapy or stereotactic radiotherapy for brain metastases

    • Last Update: 2022-10-31
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The long-term outcomes of radiation therapy are critical
    to understanding the risks and benefits of treatment for patients with brain metastases.
    The study aimed to clarify the association
    between postoperative whole-brain radiotherapy (WBRT) or stereotactic radiotherapy (SRS) and quality of life (QOL), cognitive function, and intracranial tumor control in long-term survivors of 1-4 brain metastases.

    This is a secondary analysis of a randomized phase 3 clinical trial that recruited adult patients with 1-4 brain metastases from 48 institutions in the United States and Canada, allowing one brain metastases to be removed and unremoved brain metastases to be treated
    with SRS.
    Primary endpoints were intracranial tumor control rate, toxicity, cognitive deterioration, and QOL.

    A total of 54 patients (65% women) were included in this analysis, with a median follow-up of 23.
    8 months
    .
    Patients treated with SRS had lower rates of cognitive deterioration at all time points (37 to 60 versus 75 to 91 percent)
    compared with those receiving WBRT.
    At months 3, 6, and 9, patients receiving WBRT decreased by 2 or more standard deviations (70 versus 22 percent, 46 versus 19 percent, and 50 versus 20 percent)
    on one or more cognitive tests compared with SRS.
    A 2 standard deviation decrease in at least 2 cognitive tests was associated with
    poorer 12-month emotional well-being, functional well-being, general/additional worry, and overall scores.
    At 12 months, the total control rate of intracranial tumors was 40.
    7% in the SRS alone group and 81.
    5% in the WBRT group (poor: -40.
    7%)
    .

    Overall, stereotactic radiotherapy alone reduces cognitive decline
    in long-term survivors of malignancy with brain metastases compared with whole-brain radiotherapy.
    The association between advanced cognitive decline and whole-brain radiotherapy is clinically significant
    .
    Significant cognitive decline (2SD) is associated
    with overall quality of life.
    However, whole-brain radiation therapy improves control of
    intracranial tumors.

    Original source:

    Palmer JD, Klamer BG, Ballman KV, et al.
    Association of Long-term Outcomes With Stereotactic Radiosurgery vs Whole-Brain Radiotherapy for Resected Brain Metastasis: A Secondary Analysis of The N107C/CEC.
    3 (Alliance for Clinical Trials in Oncology/Canadian Cancer Trials Group) Randomized Clinical Trial.
    JAMA Oncol.
    Published online October 20, 2022.
    doi:10.
    1001/jamaoncol.
    2022.
    5049

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.